Frontlight ResearchEarly access
Triple-negative breast cancer trials, also abroad
477 open Triple-negative breast cancer trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.
The same trial often runs in several countries
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) has 4 sites in Denmark and runs in 35 countries. If a site near you is full, another one may still take people.
See A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) in all 35 countries